7,640 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 7,640 shares of the company’s stock, valued at approximately $603,000.

Several other institutional investors have also recently made changes to their positions in the business. FMR LLC grew its position in shares of TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares in the last quarter. Vanguard Group Inc. grew its holdings in TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after buying an additional 50,673 shares in the last quarter. Eventide Asset Management LLC grew its holdings in TransMedics Group by 7.4% during the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after buying an additional 68,884 shares in the last quarter. Sandhill Capital Partners LLC grew its holdings in TransMedics Group by 4.2% during the 4th quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock valued at $60,239,000 after buying an additional 30,591 shares in the last quarter. Finally, First Light Asset Management LLC grew its holdings in TransMedics Group by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after buying an additional 136,217 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of several research analyst reports. Stephens initiated coverage on TransMedics Group in a report on Tuesday, June 4th. They set an “overweight” rating and a $151.00 price target for the company. Cantor Fitzgerald initiated coverage on TransMedics Group in a report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price target for the company. Oppenheimer raised their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Morgan Stanley raised their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, Canaccord Genuity Group raised their price target on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $133.88.

Insider Buying and Selling

In related news, Director David Weill sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $129.82, for a total transaction of $324,550.00. Following the completion of the sale, the director now directly owns 11,193 shares of the company’s stock, valued at approximately $1,453,075.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,044,932.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Weill sold 2,500 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $129.82, for a total value of $324,550.00. Following the transaction, the director now owns 11,193 shares in the company, valued at $1,453,075.26. The disclosure for this sale can be found here. In the last three months, insiders sold 290,501 shares of company stock valued at $33,268,189. Insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX stock opened at $145.96 on Wednesday. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $149.10. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. The stock has a 50 day moving average price of $122.35 and a 200 day moving average price of $95.59.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. During the same period last year, the company earned ($0.08) EPS. TransMedics Group’s quarterly revenue was up 132.9% compared to the same quarter last year. On average, research analysts forecast that TransMedics Group, Inc. will post 0.77 EPS for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.